Roll-over Study to Allow Continued Access to Ribociclib (NCT05161195)
A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the long-term safety of ribociclib (LEE011) in combination with other drugs and provide post-trial access (PTA) to participants who are currently receiving treatment with ribociclib in combination with other drugs and continuing to have clinical benefit in a Novartis-sponsored global study that has reached its primary objective(s).
Who can join: Review the eligibility criteria below.
Location: Ironwood Cancer and Research Centers — Chandler, Arizona
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (73 Sites)
Showing the first 25 of 73 sites.
- Ironwood Cancer and Research Centers — Chandler, Arizona
- Highlands Oncology Group — Fayetteville, Arkansas
- Beverly Hills Cancer Center — Beverly Hills, California
- Poudre Valley Hospital — Fort Collins, Colorado
- Mid Florida Hematology And Onc Ctr — Orange, Florida
- Summit Cancer Care — Savannah, Georgia
- John D Archbold Memorial Hospital — Thomasville, Georgia
- Duly Health and Care — Plainfield, Illinois
- Indian Univ Health Goshen Center forCancer — Goshen, Indiana
- Northern Light Mercy Hospital — Portland, Maine
- Englewood Health — Englewood, New Jersey
- The Valley Hospital-Luckow Pavillion — Paramus, New Jersey
- Eastchester Center for Cancer Care — The Bronx, New York
- University Hospitals of Cleveland Seidman Cancer Center — Cleveland, Ohio
- Oklahoma Cancer Specialists and Research Institute — Tulsa, Oklahoma
- Millennium Research Clin Develop — Houston, Texas
- Novartis Investigative Site — San Juan,
- Novartis Investigative Site — Natal, Rio Grande do Norte
- Novartis Investigative Site — Ijuí, Rio Grande do Sul
- Novartis Investigative Site — Florianópolis, Santa Catarina
- Novartis Investigative Site — São Paulo, São Paulo
- Novartis Investigative Site — São Paulo, São Paulo
- Novartis Investigative Site — Sao Jose Rio Preto,
- Novartis Investigative Site — São Paulo,
- Novartis Investigative Site — Chongqing, Chongqing Municipality
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Breast Cancer
- Assessing the Time Demands of Cancer — Birmingham, Alabama
- Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer — Birmingham, Alabama
- A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer — Commack, New York
- Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor — Washington D.C., District of Columbia
- A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer — Tucson, Arizona
Explore by condition: All Metastatic Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.